Selective Potentiation of Nav1.1 Corrects Network Function and Disease Phenotypes in a Dravet Syndrome Model

2:30 pm - Wednesday 23rd September 2026

  • Demonstrating how targeted ion channel modulation can treat clinically relevant phenotypes through integrated electrophysiology, behavioral and bioinformatics approaches 
  • Focusing on translational measures to evaluate the potential for disease modification with Nav1.1 modulation 
  • Highlighting a multi-layered preclinical strategy to evaluate target biology and therapeutic potential prior to clinical development

Speakers:

Senior Director
Xenon Pharmaceuticals